Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 8/20 | 0.54 |
| ▸ | TLR4 | O00206 | 1/20 | 0.42 |
| ▸ | TLR2 | O60603 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.40 |
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29373054 | 0.85 | KDM1A (0.52) | CYP19A1MAPTPTGES | |
| SCHEMBL22412563 | 0.85 | KDM1A (0.52) | CYP19A1MAPTPTGES | |
| SCHEMBL3873841 | 0.81 | CYP19A1 (0.51) | CYP19A1TLR4TLR2NPC1RAB9A | |
| SCHEMBL30449234 | 0.81 | CYP19A1 (0.51) | CYP19A1TLR4TLR2NPC1RAB9A | |
| SCHEMBL189978 | 0.80 | MAOB (0.47) | NPC1RAB9AMAOBCCR5HDAC8 | |
| SCHEMBL29782725 | 0.80 | CYP19A1 (0.48) | CYP19A1TLR4TLR2NPC1MAPT | |
| SCHEMBL17699810 | 0.80 | CYP19A1 (0.48) | CYP19A1TLR4TLR2NPC1MAPT | |
| SCHEMBL28484783 | 0.80 | CYP19A1 (0.44) | CYP19A1TLR4TLR2NPC1MAPT | |
| SCHEMBL21178899 | 0.79 | CYP19A1 (0.52) | CYP19A1TLR4TLR2NPC1RAB9A | |
| SCHEMBL30816726 | 0.79 | CYP19A1 (0.52) | CYP19A1TLR4TLR2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008777-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-01-08 | — | — | US | disclosed |
| EP-4638445-A1 | 1,2,4-THIAZOLIDIN-3-ONE-1,1-DIOXIDE INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | Bristol-Myers Squibb Company (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-4615839-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | Bristol-Myers Squibb Company (US) | 2025-09-17 | — | — | EP | disclosed |
| CN-120152973-A | Protein tyrosine phosphatase inhibitors, compositions, and methods of use | 百时美施贵宝公司 | 2025-06-13 | — | — | CN | disclosed |
| US-12269804-B2 | Quinoxalinone compounds, compositions, methods, and kits for increasing genome editing efficiency | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-04-08 | — | — | US | disclosed |
| US-20240238258-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240238258-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240228476-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240228476-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-11 | — | — | US | disclosed |
| WO-2024137727-A1 | 1,2,4-THIAZOLIDIN-3-ONE-1,1-DIOXIDE INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20240180886-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-06-06 | — | — | US | disclosed |
| WO-2024102794-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-05-16 | — | — | WO | disclosed |
| CN-111770921-B | Quinoxalinone compounds, compositions, methods and kits for improving genome editing efficiency | 沃泰克斯药物股份有限公司 | 2024-03-22 | — | — | CN | disclosed |
| EP-3740483-B1 | QUINOXALINONE COMPOUNDS, COMPOSITIONS, METHODS, AND KITS FOR INCREASING GENOME EDITING EFFICIENCY | VERTEX PHARMA (US) | 2023-01-11 | — | — | EP | disclosed |
| EP-3740483-A1 | QUINOXALINONE COMPOUNDS, COMPOSITIONS, METHODS, AND KITS FOR INCREASING GENOME EDITING EFFICIENCY | Vertex Pharmaceuticals Incorporated (US) | 2020-11-25 | — | — | EP | disclosed |
| US-20200361877-A1 | QUINOXALINONE COMPOUNDS, COMPOSITIONS, METHODS, AND KITS FOR INCREASING GENOME EDITING EFFICIENCY | VERTEX PHARMACEUTICALS INCORPORATED | 2020-11-19 | — | — | US | disclosed |
| CN-111770921-A | Quinoxalinone compounds, compositions, methods and kits for improving efficiency of genome editing | 沃泰克斯药物股份有限公司 | 2020-10-13 | — | — | CN | disclosed |
| WO-2019143677-A1 | QUINOXALINONE COMPOUNDS, COMPOSITIONS, METHODS, AND KITS FOR INCREASING GENOME EDITING EFFICIENCY | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361877-A1 | QUINOXALINONE COMPOUNDS, COMPOSITIONS, METHODS, AND KITS FOR INCREASING GENOME EDITING EFFICIENCY | XRCC6, LIG1, DCK | CYP19A1 2644/4885TLR4 4016/4885TLR2 4179/4885 |
| US-12269804-B2 | Quinoxalinone compounds, compositions, methods, and kits for increasing genome editing efficiency | XRCC6, LIG1, DCK | CYP19A1 2644/4885TLR4 4016/4885TLR2 4179/4885 |
| US-20240228476-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | PTPN2, PTPN22, PTPN1 | CYP19A1 2272/4885TLR4 4235/4885TLR2 3700/4885 |
| US-20260008777-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | PTPRO, PTPRC, PTPRR | CYP19A1 2484/4885TLR4 3495/4885TLR2 4302/4885 |
| US-20240180886-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | PTPN2, PTPN22, PTPN1 | CYP19A1 2272/4885TLR4 4235/4885TLR2 3700/4885 |
| US-20240238258-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | PTPN2, PTPN22, PTPN1 | CYP19A1 2272/4885TLR4 4235/4885TLR2 3700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.